Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 6 January 2009, doi:10.1136/bmj.a3145
Cite this as: BMJ 2009;338:a3145
| The first 150 words of the full text of this article appear below. |
More than two months after reporting one case of evidence-free claims to Trading Standards (for an obesity remedy) under the Unfair Trading Regulations 2008,1 we have nothing but a case number and repeated requests to resend our complaint as it has been lost several times.
In another case we challenged the claims made for a widely marketed snoring remedy. The manufacturer refused to provide any evidence, claiming that, although clinical trials had been carried out, the results were commercially sensitive and confidential. Trading Standards agreed that the manufacturer was not obliged to release the information, assuring us instead that its officer was satisfied with the evidence he had been shown. We, however, received no assurance that he could distinguish a good clinical trial from a bad one. Perhaps pharmaceutical companies should try telling the Medicines and Healthcare Products Regulatory Agency that their clinical data are too commercially sensitive to be
Leslie B Rose, clinical science consultant1, John Garrow, emeritus professor of human nutrition2
1 Pharmavision Consulting, Salisbury SP2 8NJ, 2 London
les@pharmavision-consulting.co.uk